Candida sepsis from local infection in a patient with a urostomy on SGLT2 inhibitor therapy
Ralph Wendt, Diana Schmerler, Charlotte Müller-Hechler and 3 more
International Journal of Infectious Diseases · 2020
doi:10.1016/j.ijid.2020.06.073 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Sodium–glucose co-transporter 2 (SGLT2) inhibitors exhibit impressive cardio-renal benefits in patients with a high cardiovascular risk. Genital yeast infections are important side effects of this class of drugs. We report a case of Candida glabrata sepsis secondary to a Candida infection of the urostomy of a patient on SGLT2 inhibitor therapy. In urostomy patients, one should critically evaluate the risk of mycotic infections against the cardiovascular and glycaemic benefits of SGLT2 inhibition. Urostomy patients without a high cardiovascular risk should not be treated with SGLT2 inhibitors.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.